Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)

Background: Postmenopausal osteoporosis (PMOP) is a prevalent metabolic bone disorder characterized by decreased bone mineral density (BMD) and skeletal fragility, leading to increased susceptibility to fractures. The therapeutic efficacy of zoledronic acid and denosumab, two widely used agents in t...

Full description

Saved in:
Bibliographic Details
Main Authors: Kong Lingyan, Ma Jun
Format: Article
Language:English
Published: Society of Medical Biochemists of Serbia, Belgrade 2025-01-01
Series:Journal of Medical Biochemistry
Subjects:
zoledronic acid
denosumab
postmenopausal osteoporosis
serum inflammatory cytokines
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582503587K.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items